CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke.

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Ischemic stroke is the first cause of acquired disability of the adult, the second cause of dementia and the third cause of death in the industrialized countries, what constitutes à major public health issue. Stroke is characterized by a cerebral parenchymal lesion due to an ischemic mechanism (85% of the cases) or hemorrhagic mechanism (15%). For a long time, the only approved treatment was the intravenous thrombolysis (rt-PA). Recently, thrombectomy has proven its superiority in this pathology. Cohorts of patients with stroke are rare but can be very valuable by their clinical, laboratory and imaging well documented. They are the source of new hypotheses for research or interventions as well as the quality of care assessment tool. The main objective of this project is to identify new markers: biological and imaging, treatment response and prognosis after ischemic stroke. Secondary objectives of the HIBISCUS-STROKE cohort are to establish a clinical database, completed by biological samples and by imaging data that can be used in the following areas: * Descriptive epidemiology of ischemic stroke and cerebral reperfusion, * Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of treatment in real life, costs * Assessment of the long-term effect of the treatment on the occurrence of disability, stroke recurrence and death, * Quality of life and personal, familial, professional and social consequences of stroke, * Research of new diagnostic and prognostic biomarkers, * Research projects.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age\> 18 years

• Ischemic Stroke confirmed by MRI

• Proximal arterial occlusion (ICA or M1)

• Eligible for thrombolysis and/or thrombectomy

Locations
Other Locations
France
Hôpital neurologique Pierre Wertheimer (Lyon)
RECRUITING
Bron
Contact Information
Primary
Norbert NIGHOGHOSSIAN, Prof
GHE.CICLYON@chu-lyon.fr
+33 4 72 35 71 70
Backup
Nathan MEWTON, MD, PhD
GHE.CICLYON@chu-lyon.fr
+33 472 357 231
Time Frame
Start Date: 2016-10-13
Estimated Completion Date: 2026-10
Participants
Target number of participants: 300
Related Therapeutic Areas
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov